2026-04-04T00:15:44Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/99372025-10-24T10:23:12Zcom_2072_378070com_2072_378040col_2072_378092

2025-10-24T10:23:12Z urn:hdl:11351/9937 Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes Castro, Almudena Marzal Martín, Domingo Campuzano Ruiz, Raquel Fernández Olmo, Maria Rosa Morillas, Carlos Gomez Doblas, Juan Jose Soler, María José Diabetis no-insulinodependent Sistema cardiovascular - Malalties Insuficiència renal crònica DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 DISEASES::Cardiovascular Diseases DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II ENFERMEDADES::enfermedades cardiovasculares ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica Cardiovascular; Diabetes; Glycated hemoglobin Cardiovascular; Diabetes; Hemoglobina glicosilada Cardiovascular; Diabetis; Hemoglobina glicada Type 2 diabetes (T2DM) is one of the main public health care problems worldwide. It is associated with a marked increased risk of developing atherosclerotic vascular disease, heart failure, chronic kidney disease and death. It is essential to act during the early phases of the disease, through the intensification of lifestyle changes and the prescription of those drugs that have been shown to reduce these complications, with the aim not only of achieving an adequate metabolic control, but also a comprehensive vascular risk control. In this consensus document, developed by the different specialists that treat these patients (endocrinologists, primary care physicians, internists, nephrologists and cardiologists), a more appropriate approach in the management of patients with T2DM or its complications is provided. A particular focus is given to the global control of cardiovascular risk factors, the inclusion of weight within the therapeutic objectives, the education of patients, the deprescription of those drugs without cardiovascular benefit, and the inclusion of GLP-1 receptor agonists and SGLT2 inhibitors as cardiovascular protective drugs, at the same level as statins, acetylsalicylic acid, or renin angiotensin system inhibitors. 2025-10-24T10:23:12Z 2025-10-24T10:23:12Z 2023-07-03T07:37:43Z 2023-07-03T07:37:43Z 2023-06-08 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/9937 Journal of Clinical Medicine;12(12) https://doi.org/10.3390/jcm12123925 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess MDPI Scientia